Loading data for ZYME — first visit, this takes a few seconds.
Zymeworks Inc. (ZYME)
NasdaqGS: ZYME
· Real-Time Price · USD
28.27
-0.74 (-2.55%)
At close: Aug 31, 2026, 7:31 PM
The price, the headline numbers and the latest news, in one place.
Zymeworks Inc. (ZYME) Stock Price, Analysis & Data
No data available
| Bid | 20.34 |
| Market Cap | 2.1B |
| Revenue (ttm) | 37.1M |
| Net Income (ttm) | -150M |
| 1.15 | |
| -2.02 | |
| n/a | |
| 25.21 | |
| P/B (ttm) | 26.14 |
| P/S (ttm) | 56.64 |
| Earnings Date | Nov 5, 2026 |
| Ask | 28.54 |
| Volume | 542,057 |
| Avg. Volume (20D) | 637,758 |
| Open | 28.91 |
| Previous Close | 29.01 |
| Day's Range | 28.18 - 28.91 |
| 52-Week Range | 13.60 - 30.62 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ZYME
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to th...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 28, 2017
Employees 231
Stock Exchange NasdaqGS
Ticker Symbol ZYME
Website https://www.zymeworks.com
Financial Performance
In 2025, Zymeworks's revenue was 105.97M, an increase of 38.87% compared to the previous year's 76.3M. Earnings were -81.13M, a decrease of -33.88%.
Financial StatementsEarnings Surprise
Zymeworks has released their quarterly earnings on Aug 6, 2026:
- Revenue of $4.59M misses estimates by $0, with -90.58% YoY decline.
- EPS of -0.62 misses estimates by -0.03, with -2166.67% YoY decline.
Zymeworks Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2